In the last three decades, the aberrant expression of the epidermal growth factor receptor (EGFR) has been reported in a wide range of tumours including colorectal, head and neck and lung cancers and the EGFR is currently an important therapeutic target for targeted therapy with anti-EGFR antibodies in such patients [3]. Here, EGFR is linked to lung cancer.